STRO - SUTRO BIOPHARMA, INC.
IEX Last Trade
1.86
0 0%
Share volume: 15,545
Last Updated: Fri 27 Dec 2024 08:30:26 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
0.25%
PREVIOUS CLOSE
CHG
CHG%
$1.86
0.00
0.00%
View ratios
| Fiscal Date | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | |
| Report Date | 2022-08-08 | 2022-11-08 | 2023-03-30 | 2023-05-15 | 2023-08-10 | 2023-11-13 | 2024-03-25 | 2024-05-13 | |
| Assets | |||||||||
| Total Assets | 385.620 M | 400.700 M | 406.944 M | 358.016 M | 464.899 M | 431.734 M | 470.736 M | 403.402 M | |
| Current Assets | 331.511 M | 346.553 M | 353.153 M | 304.063 M | 411.985 M | 381.254 M | 421.542 M | 354.582 M | |
| Inventories | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other Current Assets | 8.204 M | 11.064 M | 11.667 M | 17.696 M | 10.344 M | 9.476 M | 9.846 M | 10.064 M | |
| Short Term Investments | 8.204 M | 11.064 M | 11.667 M | 17.696 M | 10.344 M | 9.476 M | 9.846 M | 10.064 M | |
| Total Receivables | 97.671 M | 11.241 M | 7.122 M | 9.873 M | 9.999 M | 16.627 M | 36.078 M | 31.300 M | |
| Current Cash | 225.636 M | 324.248 M | 334.364 M | 276.494 M | 391.642 M | 355.151 M | 375.618 M | 313.218 M | |
| Total Non-current Assets | 54.109 M | 54.147 M | 53.791 M | 53.953 M | 52.914 M | 50.480 M | 49.194 M | 48.820 M | |
| Property Plant Equipment | 23.600 M | 24.281 M | 24.621 M | 24.029 M | 23.636 M | 22.344 M | 21.940 M | 20.630 M | |
| Other Assets | 29.637 M | 28.994 M | 28.298 M | 29.052 M | 28.406 M | 27.264 M | 26.382 M | 27.333 M | |
| Intangible Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Goodwill | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | |||||||||
| Total Liabilities and shareholders’ equity | 385.620 M | 400.700 M | 406.944 M | 358.016 M | 464.899 M | 431.734 M | 470.736 M | 403.402 M | |
| Total liabilities | 176.562 M | 170.974 M | 189.896 M | 172.603 M | 310.184 M | 319.387 M | 321.087 M | 305.378 M | |
| Total current liabilities | 44.572 M | 58.288 M | 66.547 M | 59.486 M | 67.125 M | 73.606 M | 93.746 M | 79.509 M | |
| Accounts Payable | 12.567 M | 12.443 M | 4.797 M | 5.058 M | 3.856 M | 5.525 M | 9.440 M | 7.511 M | |
| Other liabilities | 90.142 M | 74.865 M | 90.004 M | 85.046 M | 216.533 M | 220.917 M | 204.187 M | 204.472 M | |
| Current long term debt | 13.620 M | 15.131 M | 17.085 M | 18.493 M | 16.131 M | 13.311 M | 10.481 M | 6.673 M | |
| Long term debt | 41.848 M | 37.821 M | 33.345 M | 28.071 M | 26.526 M | 24.864 M | 23.154 M | 21.397 M | |
| Other liabilities | 90.142 M | 74.865 M | 90.004 M | 85.046 M | 216.533 M | 220.917 M | 204.187 M | 204.472 M | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 209.058 M | 229.726 M | 217.048 M | 185.413 M | 154.715 M | 112.347 M | 149.649 M | 98.024 M | |
| Common stock | 46.957 M | 52.346 M | 57.154 M | 58.723 M | 60.339 M | 60.599 M | 60.992 M | 61.458 M | |
| Retained earnings | -398.533 M | -418.021 M | -452.615 M | -502.665 M | -541.189 M | -590.473 M | -559.408 M | -617.621 M |